CoChat

A Pilot Study of Preoperative Single-Dose Ipilimumab and/or Cryoablation in Women with Early-Stage Breast Cancer with Comprehensive Immune Profiling

Open access
McArthur, Heather L., Diab, Adi, Page, David B., Yuan, Jianda, Solomon, Stephen B., Sacchini, Virgilio, Comstock, Christopher, Durack, Jeremy C., Maybody, Majid, Sung, Janice, Ginsberg, Arielle, Wong, Phillip, Barlas, Afsar, Dong, Zhiwan, Zhao, Chunjun, Blum, Brian, Patil, Sujata, Neville, Deirdre, Comen, Elizabeth A., Morris, Elizabeth A., Kotin, Alan, Brogi, Edi, Wen, Y. Hannah, Morrow, Monica, Lacouture, Mario E., Sharma, Padmanee, Allison, James P., Hudis, Clifford A., Wolchok, Jedd D., Norton, Larry · 2016 · Clinical Cancer Research
Cited by 226

The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.

Abstract

Purpose: To assess the safety and tolerability of preoperative cryoablation-mediated tumor antigen presentation and/or ipilimumab-mediated immune modulation in women with operable breast cancer. Experimental Design: In this pilot study, 19 women with breast cancer for whom mastectomy was planned were treated with preoperative tumor cryoablation (n = 7), single-dose ipilimumab at 10 mg/kg (n = 6), or both (n = 6). The primary outcome for this pilot study was safety/tolerability as defined as freedom from delays in pre-planned, curative-intent mastectomy. Exploratory studies of immune activation were performed on peripheral blood and tumor. Results: Preoperative cryoablation and/or ipilimumab were safe and tolerable, with no delays in pre-planned surgery. Grade III toxicity was seen in 1 of 19 (unrelated rash after ipilimumab). Combination therapy was associated with sustained peripheral elevations in: Th1-type cytokines, activated (ICOS+) and proliferating (Ki67+) CD4+ and CD8+ T cells, and posttreatment proliferative T-effector cells relative to T-regulatory cells within tumor. Conclusions: Preoperative cryoablation and single-dose ipilimumab are safe alone or in combination with no surgical delays incurred. Potentially favorable intratumoral and systemic immunologic effects were observed with the combination, suggesting the possibility for induced and synergistic antitumor immunity with this strategy. Clin Cancer Res; 22(23); 5729–37. ©2016 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-16-0190

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 15 references

Cited by

See all 226

Metadata

Authors
McArthur, H. L., Diab, A., Page, D. B., Yuan, J., Solomon, S. B., Sacchini, V., Comstock, C., Durack, J. C., Maybody, M., Sung, J., Ginsberg, A., Wong, P., Barlas, A., Dong, Z., Zhao, C., Blum, B., Patil, S., Neville, D., Comen, E. A., Morris, E. A., Kotin, A., Brogi, E., Wen, Y. H., Morrow, M., Lacouture, M. E., Sharma, P., Allison, J. P., Hudis, C. A., Wolchok, J. D., & Norton, L.
Venue
Clinical Cancer Research
Published
2016-11-30
Volume
22
Issue
23
Pages
5729-5737
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2513122557
Cited by
226
References
15
FWCI
9.89
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A Pilot Study of Preoperative Single-Dose Ipilimumab and/or Cryoablation in Women with Early-Stage Breast Cancer with Comprehensive Immune Profiling. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-16-0190
The paper
McArthur, H. L., Diab, A., Page, D. B., Yuan, J., Solomon, S. B., Sacchini, V., Comstock, C., Durack, J. C., Maybody, M., Sung, J., Ginsberg, A., Wong, P., Barlas, A., Dong, Z., Zhao, C., Blum, B., Patil, S., Neville, D., Comen, E. A., . . . Norton, L. (2016). A Pilot Study of Preoperative Single-Dose Ipilimumab and/or Cryoablation in Women with Early-Stage Breast Cancer with Comprehensive Immune Profiling. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-16-0190

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.